Mirabegron, a Selective β3-Adrenergic Receptor Agonist, as a Potential Anti-Obesity Drug
Obesity is becoming a global health epidemic. Brown and “beige” adipose tissue may produce heat, leading to energy expenditure enhancement and weight loss. Mirabegron, a selective β3-adrenergic receptor agonist, has been found to be effective as a brown adipose tissue activator, a “beige” cells stim...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-11-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/12/21/6897 |
| _version_ | 1797631713498628096 |
|---|---|
| author | Anna Maria Dąbrowska Jarosław Dudka |
| author_facet | Anna Maria Dąbrowska Jarosław Dudka |
| author_sort | Anna Maria Dąbrowska |
| collection | DOAJ |
| description | Obesity is becoming a global health epidemic. Brown and “beige” adipose tissue may produce heat, leading to energy expenditure enhancement and weight loss. Mirabegron, a selective β3-adrenergic receptor agonist, has been found to be effective as a brown adipose tissue activator, a “beige” cells stimulator and a metabolic homeostasis controller in animal and human studies. Although in animal studies, administration of mirabegron led to obesity improvement, significant weight loss in obese patients after mirabegron treatment has not been demonstrated so far, which may be associated with the too-short duration of the trials and the small number of participants in the studies. In humans, the most effective treatment for adipose tissue stimulation was high doses of mirabegron; however, cardiovascular side effects may limit the use of such doses, so the long-term safety must be evaluated. In cases of tachycardia or blood pressure elevation, the co-administration of a β1-adrenergic receptor blocker may be useful. It should be checked whether smaller doses of mirabegron, taken for a longer time, will be sufficient to stimulate brown and “beige” adipose tissue, leading to weight loss. The introduction of mirabegron into obesity treatment in the future will require long-term trials with larger numbers of subjects, to assess mirabegron efficacy, tolerability, and safety. |
| first_indexed | 2024-03-11T11:26:09Z |
| format | Article |
| id | doaj.art-46846f7d748f4eb1886a2c5ab5371f51 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-11T11:26:09Z |
| publishDate | 2023-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-46846f7d748f4eb1886a2c5ab5371f512023-11-10T15:06:50ZengMDPI AGJournal of Clinical Medicine2077-03832023-11-011221689710.3390/jcm12216897Mirabegron, a Selective β3-Adrenergic Receptor Agonist, as a Potential Anti-Obesity DrugAnna Maria Dąbrowska0Jarosław Dudka1Department of Toxicology, Medical University of Lublin, Jaczewskiego Street 8b, 20-090 Lublin, PolandDepartment of Toxicology, Medical University of Lublin, Jaczewskiego Street 8b, 20-090 Lublin, PolandObesity is becoming a global health epidemic. Brown and “beige” adipose tissue may produce heat, leading to energy expenditure enhancement and weight loss. Mirabegron, a selective β3-adrenergic receptor agonist, has been found to be effective as a brown adipose tissue activator, a “beige” cells stimulator and a metabolic homeostasis controller in animal and human studies. Although in animal studies, administration of mirabegron led to obesity improvement, significant weight loss in obese patients after mirabegron treatment has not been demonstrated so far, which may be associated with the too-short duration of the trials and the small number of participants in the studies. In humans, the most effective treatment for adipose tissue stimulation was high doses of mirabegron; however, cardiovascular side effects may limit the use of such doses, so the long-term safety must be evaluated. In cases of tachycardia or blood pressure elevation, the co-administration of a β1-adrenergic receptor blocker may be useful. It should be checked whether smaller doses of mirabegron, taken for a longer time, will be sufficient to stimulate brown and “beige” adipose tissue, leading to weight loss. The introduction of mirabegron into obesity treatment in the future will require long-term trials with larger numbers of subjects, to assess mirabegron efficacy, tolerability, and safety.https://www.mdpi.com/2077-0383/12/21/6897obesityβ3-adrenergic receptor agonistmirabegronbrown adipose tissue“beige” adipose tissue |
| spellingShingle | Anna Maria Dąbrowska Jarosław Dudka Mirabegron, a Selective β3-Adrenergic Receptor Agonist, as a Potential Anti-Obesity Drug Journal of Clinical Medicine obesity β3-adrenergic receptor agonist mirabegron brown adipose tissue “beige” adipose tissue |
| title | Mirabegron, a Selective β3-Adrenergic Receptor Agonist, as a Potential Anti-Obesity Drug |
| title_full | Mirabegron, a Selective β3-Adrenergic Receptor Agonist, as a Potential Anti-Obesity Drug |
| title_fullStr | Mirabegron, a Selective β3-Adrenergic Receptor Agonist, as a Potential Anti-Obesity Drug |
| title_full_unstemmed | Mirabegron, a Selective β3-Adrenergic Receptor Agonist, as a Potential Anti-Obesity Drug |
| title_short | Mirabegron, a Selective β3-Adrenergic Receptor Agonist, as a Potential Anti-Obesity Drug |
| title_sort | mirabegron a selective β3 adrenergic receptor agonist as a potential anti obesity drug |
| topic | obesity β3-adrenergic receptor agonist mirabegron brown adipose tissue “beige” adipose tissue |
| url | https://www.mdpi.com/2077-0383/12/21/6897 |
| work_keys_str_mv | AT annamariadabrowska mirabegronaselectiveb3adrenergicreceptoragonistasapotentialantiobesitydrug AT jarosławdudka mirabegronaselectiveb3adrenergicreceptoragonistasapotentialantiobesitydrug |